 Home > Medical News > Latest Medical News > Pfizer's PF-06882961 clinical trial application was approved for the treatment of type 2 diabetes

Pfizer's PF-06882961 clinical trial application was approved for the treatment of type 2 diabetes

 Last Update: 2021-03-27
 Source: Internet
 Author: User

Tags

boron weight loss

safety data sheets include

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 17, the CDE official website showed that Pfizer's PF-06882961 tablet (danuglipron) clinical trial application has been granted the default permission, and it plans to conduct clinical research on the treatment of type 2 diabetes.

Danuglipron (code name: PF-06882961 tablets) is an oral small molecule GLP-1 receptor agonist developed by Pfizer.

The potential advantages of danuglipron include: ① It can achieve effective control of blood sugar and weight; ② Tolerability and safety are similar to peptide GLP-1RA, and the oral dosage form is convenient to take; ③ Good bioavailability; ④ Different from oral macromolecules GLP-1RA is not restricted by food or dosage.

Pfizer announced at the online Investor Day event (Investor Day) held in August 2020

danuglipron Phase I clinical study data.

At present, Pfizer has launched a phase II clinical study to test the effect of danuglipron in the treatment of diabetic patients.

Prior to this, Novo Nordisk Rybelsus (oral smeglutide, once a day) has been approved for marketing by the FDA and is currently the only oral GLP-1 receptor agonist on the market.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.